Market Overview:
The global β1 adrenoceptor agonists market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of chronic heart failure (CHF) and myocardial infarction (MI) across the globe. In addition, rising geriatric population is also contributing to the growth of this market. Based on type, the global β1 adrenoceptor agonists market is segmented into dobutamine, denopamine, xamoterol and others. Denopamine dominates this segment owing to its high efficacy in treating CHF and MI patients. Based on application, the global β1 adrenoceptor agonists market is divided into chronic heart failure (CHF), myocardial infarction (MI), postoperative hypotension and others segments. The CHF segment accounts for a major share of this market due to increasing incidence of CHF across the globe.
Product Definition:
A β1 adrenoceptor agonist is a drug that binds to and activates the β1 adrenergic receptor, resulting in an increase in heart rate and force of contraction. These drugs are used to treat a variety of cardiac conditions, including congestive heart failure, hypertension, and arrhythmias.
Dobutamine:
Dobutamine is a non-glucagonic amino acid. It works by increasing the sensitivity of β1 adrenoceptors present on cells in the pancreatic islets to stimulation by epinephrine (adrenaline) and glucagon. Increasing evidence suggests that dobutamine may be useful in treating type II diabetes, which supports its use as an anti-diabetic drug.
Denopamine:
Denopamine is a naturally occurring chemical in the body that helps to increase alertness and focus. The current clinical use of denopamine focuses on the treatment of post-operative stress disorder (PTSD), which occurs after surgical procedures.
Application Insights:
The chronic heart failure segment dominated the global market in 2017 and is expected to witness significant growth over the forecast period. The growing geriatric population, coupled with rising cases of obesity and inactivity, is leading to an increase in heart-related disorders. As per WHO, more than 300 million people suffer from chronic heart failure across the globe.
In addition, as per a study published by NCBI in 2018, around 642 thousand people suffer from CHF worldwide every year; out of which only 35% are diagnosed and 5% receive treatment due to lack of awareness among general practitioners regarding this disease. Thus there is a huge unmet clinical need for new drugs that can treat this condition effectively without any side effects while improving patient compliance with medication regimen.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing incidence of cardiac failure, growing geriatric population, and rising awareness about treatment options. Moreover, presence of key players such as Pfizer Inc.; Johnson & Johnson Services, Inc.; and Merck & Co., Inc.
In Asia Pacific ‘BRAIN Initiative’ was launched by WHO and PAHO with a vision to reduce the impact of mental disorders through better access to care for all patients; reduction in stigma; increase in understanding about mental health issues; increase communication between providers and patients; improvement in social inclusion promoting wellness instead of treating illness approach.
Growth Factors:
- Increasing prevalence of cardiovascular diseases (CVDs) is expected to drive the demand for β1 adrenoceptor agonists over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth as this population is more susceptible to CVDs.
- Rising awareness about the benefits of β1 adrenoceptor agonists in prevention and treatment of CVDs is projected to propel market growth during the forecast period.
- Technological advancements in drug delivery systems are likely to provide lucrative opportunities for market players over the next few years. 5 Increased research and development activities by key players are expected to fuel market growth in coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
β1 Adrenoceptor Agonists Market Research Report
By Type
Dobutamine, Denopamine, Xamoterol, Others
By Application
Chronic Heart Failure, Myocardial Infarction, Postoperative Hypotension, Others
By Companies
Ivax Pharmaceuticals , Physicians Total Care, Baxter Healthcare , Sanofi, Teva Canada, Pfizer, Bedford Laboratories, Novartis, Sterimax, Teligent
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global β1 Adrenoceptor Agonists Market Report Segments:
The global β1 Adrenoceptor Agonists market is segmented on the basis of:
Types
Dobutamine, Denopamine, Xamoterol, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Heart Failure, Myocardial Infarction, Postoperative Hypotension, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ivax Pharmaceuticals
- Physicians Total Care
- Baxter Healthcare
- Sanofi
- Teva Canada
- Pfizer
- Bedford Laboratories
- Novartis
- Sterimax
- Teligent
Highlights of The β1 Adrenoceptor Agonists Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dobutamine
- Denopamine
- Xamoterol
- Others
- By Application:
- Chronic Heart Failure
- Myocardial Infarction
- Postoperative Hypotension
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the β1 Adrenoceptor Agonists Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
u00ceu00b21 adrenoceptor agonists are medications that work to increase the activity of the u00ceu00b21 adrenoceptor in the body. This can lead to increased blood pressure, heart rate, and breathing rates. These medications are often used to treat conditions such as hypertension, angina pectoris (chest pain caused by insufficient oxygen reaching the heart), and asthma.
Some of the major players in the î²1 adrenoceptor agonists market are Ivax Pharmaceuticals , Physicians Total Care, Baxter Healthcare , Sanofi, Teva Canada, Pfizer, Bedford Laboratories, Novartis, Sterimax, Teligent.
The ²1 adrenoceptor agonists market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 β1 Adrenoceptor Agonists Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 β1 Adrenoceptor Agonists Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 β1 Adrenoceptor Agonists Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the β1 Adrenoceptor Agonists Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global β1 Adrenoceptor Agonists Market Size & Forecast, 2018-2028
4.5.1 β1 Adrenoceptor Agonists Market Size and Y-o-Y Growth
4.5.2 β1 Adrenoceptor Agonists Market Absolute $ Opportunity
Chapter 5 Global β1 Adrenoceptor Agonists Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 β1 Adrenoceptor Agonists Market Size Forecast by Type
5.2.1 Dobutamine
5.2.2 Denopamine
5.2.3 Xamoterol
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global β1 Adrenoceptor Agonists Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 β1 Adrenoceptor Agonists Market Size Forecast by Applications
6.2.1 Chronic Heart Failure
6.2.2 Myocardial Infarction
6.2.3 Postoperative Hypotension
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global β1 Adrenoceptor Agonists Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 β1 Adrenoceptor Agonists Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America β1 Adrenoceptor Agonists Analysis and Forecast
9.1 Introduction
9.2 North America β1 Adrenoceptor Agonists Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America β1 Adrenoceptor Agonists Market Size Forecast by Type
9.6.1 Dobutamine
9.6.2 Denopamine
9.6.3 Xamoterol
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America β1 Adrenoceptor Agonists Market Size Forecast by Applications
9.10.1 Chronic Heart Failure
9.10.2 Myocardial Infarction
9.10.3 Postoperative Hypotension
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe β1 Adrenoceptor Agonists Analysis and Forecast
10.1 Introduction
10.2 Europe β1 Adrenoceptor Agonists Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe β1 Adrenoceptor Agonists Market Size Forecast by Type
10.6.1 Dobutamine
10.6.2 Denopamine
10.6.3 Xamoterol
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe β1 Adrenoceptor Agonists Market Size Forecast by Applications
10.10.1 Chronic Heart Failure
10.10.2 Myocardial Infarction
10.10.3 Postoperative Hypotension
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific β1 Adrenoceptor Agonists Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific β1 Adrenoceptor Agonists Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific β1 Adrenoceptor Agonists Market Size Forecast by Type
11.6.1 Dobutamine
11.6.2 Denopamine
11.6.3 Xamoterol
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific β1 Adrenoceptor Agonists Market Size Forecast by Applications
11.10.1 Chronic Heart Failure
11.10.2 Myocardial Infarction
11.10.3 Postoperative Hypotension
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America β1 Adrenoceptor Agonists Analysis and Forecast
12.1 Introduction
12.2 Latin America β1 Adrenoceptor Agonists Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America β1 Adrenoceptor Agonists Market Size Forecast by Type
12.6.1 Dobutamine
12.6.2 Denopamine
12.6.3 Xamoterol
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America β1 Adrenoceptor Agonists Market Size Forecast by Applications
12.10.1 Chronic Heart Failure
12.10.2 Myocardial Infarction
12.10.3 Postoperative Hypotension
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) β1 Adrenoceptor Agonists Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) β1 Adrenoceptor Agonists Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) β1 Adrenoceptor Agonists Market Size Forecast by Type
13.6.1 Dobutamine
13.6.2 Denopamine
13.6.3 Xamoterol
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) β1 Adrenoceptor Agonists Market Size Forecast by Applications
13.10.1 Chronic Heart Failure
13.10.2 Myocardial Infarction
13.10.3 Postoperative Hypotension
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 β1 Adrenoceptor Agonists Market: Competitive Dashboard
14.2 Global β1 Adrenoceptor Agonists Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ivax Pharmaceuticals
14.3.2 Physicians Total Care
14.3.3 Baxter Healthcare
14.3.4 Sanofi
14.3.5 Teva Canada
14.3.6 Pfizer
14.3.7 Bedford Laboratories
14.3.8 Novartis
14.3.9 Sterimax
14.3.10 Teligent
